^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer

    Excerpt:
    ...Evaluation of the HER-2 gene copy number and amplification`DNA Extraction and Mutational Analysis of EGFR and HER-2`Toxicity evaluation`Determination of plasma HGF pre and post-treatment concentration...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Oncol
    Title:

    Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study

    Published date:
    05/07/2021
    Excerpt:
    We retrospectively included metastatic NSCLC patients harboring HER2 alterations who treated with afatinib….For HER2-amplified patients, the ORR was 33% (95% CI, 14-61%), the median PFS was 3.3 months (95% CI, 2.6-4.0), and the median OS was 13.4 months (95% CI, 0-27.6).
    DOI:
    10.3389/fonc.2021.657283